The World’s Largest 36,000L Biomanufacturing Line Using Single-use Bioreactors Launches GMP Operation at WuXi Biologics

WuXi Biologics announced on February 08th that its MFG5 Drug Substance (DS) manufacturing facility in China has successfully launched GMP operation, with the capacity of 36,000L, deploying nine 4,000L single-use bioreactors. As a major landmark in the company’s global capacity planning, the GMP launch of MFG5 brings WuXi Biologics’ current capacity to 90,000L, greatly enhancing the capability to enable global partners. Employing advanced manufacturing and quality systems, this new 70,000m² facility is the largest DS facility within WuXi Biologics’ global network, and also the world’s largest GMP facility using single-use bioreactors. Leveraging its state-of-the-art design, MFG5 will provide flexible and high-quality manufacturing solutions that cater to a range of customer needs, including different manufacturing scale of  4,000L, 8,000L, 12,000L and 16,000L. The GMP launch of MFG5 showcases WuXi Biologics’ industry-leading Scale-out strategy of combining multiple single-use bioreactors for large-scale biologics manufacturing. This approach is more productive and environmentally friendly, compared with using traditional stainless-steel bioreactors.

For further information, see PRnewswire (https://www.prnewswire.com/news-releases/the-worlds-largest-36-000l-biomanufacturing-line-using-single-use-bioreactors-launches-gmp-operation-at-wuxi-biologics-301224382.html)

Leave a Reply

Your email address will not be published. Required fields are marked *